Эффективность и безопасность ультрамелкодисперсного беклометазона дипропионата у больных бронхиальной астмой (Обзор литературы)

бронхиальная астма

1. Global initiative for asthma. — NHLB/WHO Workshop report. — National Heart Lung Blood Institute, Publication number 02-3659, 2002.

2. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157 (3, pt 2): 1S-53S.

3. Suissa S., Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J. Allergy Clin. Immunol. 2001; 107 (6): 937-944.

4. Suissa S., Ernst P., Benayoun S. et al. Low-dose of inhaled corticosteroids and prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332-336.

5. Leach C.L. Improved delivery of inhaled steroids to the large and small airways. Respir. Med. 1998; 92 (suppl. A): 3-8.

6. Goodman D., Israel E., Rosenberg M. et al. The influence of age, diagnosis and gender on proper use of metered dose inhalers. Am. J. Respir. Crit. Care Med. 1994; 150: 1256-1261.

7. Kamps A.W., van Ewjil B., Roorda R.J. et al. Poor inhalation technique even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 2000; 29 (1): 39-42.

8. Shresthna M., Parupia H., Andrews B. et al. Metered dose inhaler technique of patients in urban ED: prevalence of incorrect technique and attempt at education. Am. J. Emerg. Med. 1996; 14 (4): 380-384.

9. Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Respir. Med. 1998; 92 (suppl. A): 23-31.

10. Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoro-alkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343-351.

11. Busse W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propelent. J. Allergy Clin. Immunol. 1999; 104 (6): 1215-1222.

12. Firemann P, Prenner B.M., Vinsken W. et al. Long term safety and efficacy of chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Clin. Immunol. 2001; 86 (5): 557-565.

13. Magnussen H. E quivalent asthma control after dose reduction with HFA 134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir. Med. 2000. 94: 561-567.

14. Juniper E., Price D., Stampone P.A. et al. Clinically important improvement in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate tp approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121 (6): 1824-1832.

15. Aubier M., Wettenger R., Gans S.J. Efficacy of HFA-beclametha-sone dipropionate extra-fine aerosol (800 md/day) versus HFA-fluticasone propionate (1000 md/day) in patients with asthma. Respir. Med. 2001; 95 (1): 212-220.

16. Worth H., Muir J.F., Pieters W.R. Comparison of Hydro-fluoroalkane-Beclomethasone Dipropionate AutohalerTM with Budesonide Turbuhaler TM in asthma control. Respiration 2001; 68: 517-526.

17. Thompson P., Davies R.J., Yong W.F. et al. Safety of hydroflu-oroalkane-134 a beclomethasone propionate extrafine aerosol. Respir. Med. 1998; 92 (suppl.A): 33-39.

18. Reichel W.t Dahl R., Ringdal N. et al. Extrafine beclometasone dipropionate breath actuated inhaler (400 mcg/day) versus budesonide dry power inhaler (800 mcg/day) in asthma. Int. J. Clin. Pract. 2001; 55 (1): 100-106.

19. Rocca-Serra J.P., Vicaut E, Lefrancois G, Umile A. Efficacy and tolerability of new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Comparison with Beclomethasone CFC. Clin. Drug Invest. 2002; 22 (10): 653-665.

20. Lenney J., Innes J., Cropmton G.K. Inappropriate inhaler use: assessment of use and preference of seven inhalation devices. Respir. Med. 2000; 94: 496-500.

21. Price D., Thomas M., Mitchell G. et al. Improvement of asthma control with breath-actuated pressurized metered dose inhaler (BAI); a prescribing claims study of 5556 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. Respir. Med. 2003; 97 (1): 12-19.

22. Haycox A., Mitchel G., Nizol C. et al. Cost effectiveness of asthma treatment with breath-actuated pressurized metered dose inhaler (BAI)-a prescribing claim study of 1856 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. J. Med. Econom. 2002; 5 (1): 65-77.

23. Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000; 94 (suppl. D): S13-S16

24. Edbasker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 (suppl 4): 7-16.

25. Kelly H.W. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled steroids. J. Allergy Clin. Immunol. 1998; 102 (4, pt 2): S36-S5I.

26. Ganderton D., Lewis D., Davies R. Modulite®: a mean of designing the aerosol generated by pressurized metered dose inhalers. Respir. Med. 2002; 96 (suppl. D): S3-S8.